ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDONOVO THERAPEUTICS, INC.
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $135.08K
- P/E (TTM)
- –
- Dividend yield
- –
Endonovo Therapeutics statistics
Financials through Dec 31, 2022, price as of Oct 19, 2026, median of Electromedical & Electrotherapeutic Apparatus companies for comparison
Valuation
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Market Cap | $31.88K | $229.23M |
| Enterprise Value | $31.78K | $194.73M |
| PS Ratio | 0.24 | 3.14 |
Enterprise value
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.23 | 2.93 |
Income (trailing twelve months)
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Revenue | $135.36K | $102.39M |
| Gross Profit | $125.37K | $60.36M |
| Operating Income | -$3.26M | -$4.31M |
| Pretax Income | -$18.47M | -$2.26M |
| Net Income | -$18.47M | -$6.57M |
| EBITDA | -$2.62M | -$1.98M |
Margins
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 92.6% | 55.1% |
| Operating Margin | -2411.7% | -6.04% |
| Pretax Margin | -13649.2% | -4.11% |
| Profit Margin | -13649.2% | -10.5% |
| EBITDA Margin | -1933.7% | -2.67% |
Returns
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -1123.6% | -13.3% |
Growth
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 85.2% | 8.85% |
| Revenue Growth (3Y CAGR) | -24.1% | 7.08% |
Balance sheet
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $98 | $37.33M |
| Net Cash (Debt) | $98 | $3.92M |
| Net Cash Per Share | $0.00 | $0.28 |
| Equity (Book Value) | -$32.18M | $57.36M |
| Book Value Per Share | -$0.10 | $2.81 |
| Tangible Book Value | -$33.45M | $10.71M |
| Working Capital | -$33.37M | $54.64M |
Financial position
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.00 | 2.50 |
| Quick Ratio | 0.00 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$678.84K | -$653.46K |
Efficiency
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.59 |
| Revenue Per Employee | $135.36K | $322.75K |
| Profits Per Employee | -$18.47M | -$52.11K |
| Employee Count | 1 | 197 |
Dividends and yields
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -57960.0% | -6.92% |
| Buyback Yield | -445.5% | 0.78% |
| Shareholder Yield | -445.5% | 0.84% |
Shares
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 318,752,000 | 44,856,700 |
| Shares Change (YoY) | 132.6% | 3.35% |
| Float | 318,752,000 | 36,934,400 |
| Shares Held by Insiders | 0.00% | 10.6% |
Scores
| Measure | Endonovo Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -121.63 | 1.95 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from Endonovo Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.